Marcus Klein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcus Klein has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Askandar Tjokroprawiro
Internal Medicine Department, Airlangga University/Dr. Soetomo General Hospital, Jawa Timur, Indonesia
1 shared publication- Chul-Hee Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
1 shared publication Han‐Jin Oh
Cheil General Hospital & Women’s Healthcare Center, Seoul, Korea
1 shared publicationKevin Eng‐Kiat Tan
Mount Elizabeth Medical Centre, Singapore
1 shared publicationKyung‐Ah Han
Eulji General Hospital
1 shared publicationRadhakrishna Sothiratnam
Columbia Asia Hospital, Negeri Sembilan, Malaysia
1 shared publication
Latest Publications
- Open Access
- 28 November 2012
- Published by Wiley in Journal of Diabetes
- Vol. 4 (4) , 395-406
Safety, tolerability, and efficacy of metformin extended‐release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. Data from 3556 patients treated with once-daily MXR for 12 weeks, or until discontinuation, were analyzed. Treatment with MXR was well tolerated, with 97.4% of patients completing 12 weeks of treatment. Only 3.3% of patients experienced one or more gastrointestinal (GI) side-effects and only 0.7% of patients discontinued for this reason (primary endpoint). The incidence of GI side-effects and related discontinuations appeared to be considerably lower during short-term MXR therapy than during previous treatment (mean 2.71 years' duration), most commonly with immediate-release metformin. A 12-week course of MXR therapy also reduced HbA1c and fasting glucose levels from baseline. The present study provides new insights into the incidence of GI side-effects with MXR in Asian patients with T2DM and on the tolerability of MXR in non-Caucasian populations. Specifically, these data indicate that once-daily MXR not only improves measures of glycemic control in Asian patients with T2DM, but also has a favorable GI tolerability profile that may help promote enhanced adherence to oral antidiabetic therapy.
- 28 November 2012
- Published by Wiley in Journal of Diabetes
- Vol. 4 (4) , 395-406
Open AccessSafety, tolerability, and efficacy of metformin extended‐release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
The aim of the present prospective observational study was to assess the tolerability and antihyperglycemic efficacy of metformin extended-release (MXR) in the routine treatment of patients with type 2 diabetes mellitus (T2DM) from six Asian countries. Data from 3556 patients treated with once-daily MXR for 12 weeks, or until discontinuation, were analyzed. Treatment with MXR was well tolerated, with 97.4% of patients completing 12 weeks of treatment. Only 3.3% of patients experienced one or more gastrointestinal (GI) side-effects and only 0.7% of patients discontinued for this reason (primary endpoint). The incidence of GI side-effects and related discontinuations appeared to be considerably lower during short-term MXR therapy than during previous treatment (mean 2.71 years' duration), most commonly with immediate-release metformin. A 12-week course of MXR therapy also reduced HbA1c and fasting glucose levels from baseline. The present study provides new insights into the incidence of GI side-effects with MXR in Asian patients with T2DM and on the tolerability of MXR in non-Caucasian populations. Specifically, these data indicate that once-daily MXR not only improves measures of glycemic control in Asian patients with T2DM, but also has a favorable GI tolerability profile that may help promote enhanced adherence to oral antidiabetic therapy.